Aug 17, 2025 • Benzinga
NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 09, 2025 • Benzinga
NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO - NeoGenomics ( NASDAQ:NEO )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ( "NeoGenomics" or the "Company" ) NEO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Jul 30, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Down 29.2% in 4 Weeks, Here's Why NeoGenomics ( NEO ) Looks Ripe for a Turnaround
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Jul 29, 2025 • Benzinga
SOMEWHAT-BEARISH
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Fulcrum Therapeutics ( NASDAQ:FULC ) , Exelixis ( NASDAQ:EXEL )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Whirlpool Corporation WHR fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 earnings guidance.
Jul 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
NeoGenomics ( NEO ) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 24, 2025 • Zacks Commentary
NEUTRAL
Analysts Estimate Amicus Therapeutics ( FOLD ) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.